New Rosacea Treatments
One of the hottest areas of interest online for rosacea sufferers is new rosacea treatments. From the industry heavyweights like Galderma, Allergan, Bayer, Valeant and Stiefel to little companies like MooGoo there is a lot of interest in the up and coming rosacea treatments. See below for the latest information about what is just over the horizon.
Recent Rosacea Blog Posts
A drug that is said to inhibit nuclear factor kappa beta (NFkB), is to be trialed as a rosacea treatment. The new treatment, code named ACU-D1 will be tested as a treatment primarily for the papules and pustules of rosacea. Clinical Trial NCT03064438 Efficacy of Accu-D1 in the Treatment of Acne Rosacea The study evaluates the safety, […]
A press release today highlighting a new drug, based on Arazine, that is claimed to help both the redness and papules and pustules of rosacea through its ability to down regulate G-protein coupled receptor (GPCR) signaling. The company developing DMT 210, Dermata, is releasing results from their phase 1 trials, and are looking to commence phase 2 trials […]
Dr. Reddy has listed a clinical trial to continue to investigate Topical Itraconazole 5% as a treatment for the papules and pustules of rosacea. So we can add DFD-04 to the list of new drugs in development for rosacea. From Dr. Reddy’s 2015 Investor Day Presentation. We target underserved segments within large disease areas both […]
A 2015 paper details 2 patients with severe flushing and redness being treated with injections of Botox. The first patient had suffered 2 years of flushing and erythema triggered by heat, sun exposure, stress, spicy food and cosmetics. The second patient had suffered from 3 years of redness and flushing. Both had tried a series of […]
Allergan today have confirmed that a new drug application for their 1% oxymetazoline hcl cream has been formally lodged with the FDA. The prediction from Allergan is that the approval will come in the first half of 2017. This is the first confirmation that Allergan has settled on a 1% formulation of oxymetazoline hydrochloride, having […]